E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedReviewed
A Quick and Practical Approach to Secure a Chronic Fatigue Syndrome Diagnosis: The Novel Functional Limitation Index.
Corbalán, Juan Antonio, Feltes, Gisela, Silva, Daniela et al. · Journal of clinical medicine · 2023 · DOI
Quick Summary
Researchers developed a simple test called the Functional Limitation Index (FLI) to help doctors diagnose ME/CFS more quickly and objectively. The test uses measurements from exercise testing and breathing tests to identify how much a person's physical function is impaired. In their study, the FLI successfully distinguished ME/CFS patients from healthy people and athletes with high accuracy.
Why It Matters
ME/CFS diagnosis currently relies on clinical criteria and exclusion of other conditions, creating diagnostic delays. An objective, physiologically-based parameter could accelerate diagnosis, reduce healthcare burden, and facilitate earlier intervention. This tool could improve care access for patients who often face delayed recognition of their condition.
Observed Findings
- CFS patients showed significantly higher FLI scores (2.7) compared to non-CFS controls (1.2), p < 0.001.
- The FLI demonstrated superior diagnostic accuracy (AUC 0.94) compared to individual spirometric variables.
- Using an FLI cutoff of 1.66, sensitivity was 87.4% and specificity was 86.4%.
- CFS patients demonstrated lower functional class and worse performance across all measured physical parameters.
- 85% of the CFS group were female compared to 25.5% of controls, suggesting potential sex-related differences in diagnosis or disease presentation.
Inferred Conclusions
- The FLI provides an objective, single-day physiological parameter that can accurately distinguish ME/CFS patients from healthy controls and athletes.
- The FLI may support clinical diagnosis and reduce diagnostic uncertainty in patients with suspected ME/CFS.
- This index could facilitate earlier recognition and referral of ME/CFS cases in clinical practice.
Remaining Questions
- Does the FLI perform equally well across different age groups, ethnic populations, and healthcare settings outside specialized referral centers?
- Can the FLI predict disease severity, prognosis, or response to treatments in ME/CFS patients?
What This Study Does Not Prove
This study does not prove that the FLI measures the underlying cause of ME/CFS or that abnormal FLI is specific to ME/CFS—it only shows association in this particular patient population. The study cannot establish whether FLI changes over time or predicts treatment response. Cross-sectional design prevents determining whether FLI abnormalities precede or follow ME/CFS onset.
Tags
Symptom:Post-Exertional MalaiseFatigue
Method Flag:Strong PhenotypingSex-StratifiedWeak Case DefinitionExploratory Only
Biomarker:Blood Biomarker
Metadata
- DOI
- 10.3390/jcm12227157
- PMID
- 38002769
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.